Analyzing Compass Therapeutics (NASDAQ:CMPX) and NKGen Biotech (NYSE:NKGN)

Compass Therapeutics (NASDAQ:CMPX) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Compass Therapeutics and NKGen Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	0	0	3	0	3.00
NKGen Biotech	0	0	0	0	N/A

Compass Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 316.67%. Given Compass Therapeutics’ higher probable upside, equities analysts clearly believe Compass Therapeutics is more favorable than NKGen Biotech.

Volatility and Risk

Compass Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Valuation & Earnings

This table compares Compass Therapeutics and NKGen Biotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850,000.00	297.84	-$42.49 million	($0.36)	-5.11
NKGen Biotech	$80,000.00	121.77	-$82.94 million	N/A	N/A

Compass Therapeutics has higher revenue and earnings than NKGen Biotech.

Profitability

This table compares Compass Therapeutics and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-30.89%	-29.36%
NKGen Biotech	N/A	N/A	-479.36%

Institutional & Insider Ownership

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 30.0% of Compass Therapeutics shares are owned by company insiders. Comparatively, 20.0% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Compass Therapeutics beats NKGen Biotech on 8 of the 10 factors compared between the two stocks.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.